C
1.36
-0.01 (-0.73%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Channel Therapeutics Corporatio | - | - |
AIStockmoo 评分
-0.4
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.38 |
|
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 58.22% |
| 机构持股比例 | 12.68% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 17 Apr 2025 | 公告 | Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合